Lexicon Pharmaceuticals has an important data readout coming in the first quarter for a Phase IIb study testing pilavapadin, or LX9211, for diabetic peripheral neuropathic pain (DPNP). If that trial reads out positively, Lexicon will have more optionality because LX9211 is the company’s sole near-term clinical catalyst.
Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain
CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.
More from Interviews
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
The founder and CEO of Ultragenyx talked with Scrip as the company approaches a pivotal data readout and awaits US FDA action on its first gene therapy.
More from Conferences
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.